Evidence map›Paper›PMID 26755165›Full record

Trial reportRadiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology2016

Quality of life outcomes from a dose-per-fraction escalation trial of hypofractionation in prostate cancer.

Jeffrey V Brower, Jeffrey D Forman, Patrick A Kupelian, Daniel G Petereit, Vinai Gondi, Colleen A Lawton, Nick Anger, Sandeep Saha, Rick Chappell, Mark A Ritter

Registry-linked trialAbstract readClinical Trial, Phase IClinical Trial, Phase IIMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00214097 (Phase I/II Trial Examining Dose-per-Fraction Escalation Using Intensity Modulated Radiation Therapy in the Treatment of Prostate Cancer), which is not on this map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00214097 phase1 / phase2completednot on this map

Phase I/II Trial Examining Dose-per-Fraction Escalation Using Intensity Modulated Radiation Therapy in the Treatment of Prostate Cancer

TypeinterventionalSponsorUniversity of Wisconsin, MadisonRan2002 to 2017Enrolled347ConditionsProstate CancerArmsRadiotherapy
3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Hypofractionated Radiation Therapy for Localized Prostate Cancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2018
    Article
  6. Normal tissue sparing using different techniques for prostate irradiation.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jeffrey V BrowerDepartment of Human Oncology, University of Wisconsin Carbone Cancer Center, Madison, United States.
Jeffrey D FormanWayne State University, Detroit, United States.
Patrick A KupelianUCLA Medical Center, Los Angeles, United States.
Daniel G PetereitJohn T. Vucurevich Cancer Center Institute, Rapid City, United States.
Vinai GondiCDH Cancer Center, Warrenville, United States.
Colleen A LawtonMedical College of Wisconsin, Milwaukee, United States.
Nick AngerDepartment of Human Oncology, University of Wisconsin Carbone Cancer Center, Madison, United States.
Sandeep SahaDepartment of Biostatistics and Medical Informatics, University of Wisconsin, Madison, United States.
Rick ChappellDepartment of Biostatistics and Medical Informatics, University of Wisconsin, Madison, United States.
Mark A RitterDepartment of Human Oncology, University of Wisconsin Carbone Cancer Center, Madison, United States. Electronic address: ritter@humonc.wisc.edu.

Funding

TOMOTHERAPY BASED DOSE PER FRACTION ESCALATION IN NSCLCP01CA088960 · NCI · UNIVERSITY OF WISCONSIN MADISON · PI MEHTA, MINESH P. · 2001 to 2005
$8.9M
Hypofractionated IMRT for Localized Prostate CancerR01CA106835 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI RITTER, MARK A · 2005 to 2008
$940k
NCI NIH HHS P01 CA088960NCI NIH HHS P01 CA88960NCI NIH HHS R01 CA106835NCI NIH HHS R01CA106835
6 · The paper itself

Abstract

objectiveThis multi-institutional phase I/II trial explored patient-assessed tolerance of increasingly hypofractionated (HPFX) radiation for low/intermediate risk prostate cancer.

methods347 patients enrolled from 2002 to 2010. Three increasing dose-per-fraction schedules of 64.7 Gy/22 fx, 58.08 Gy/16 fx and 51.6 Gy/12 fx were each designed to yield equivalent predicted late toxicity. Three quality of life (QoL) surveys were administered prior to treatment and annually upto 3 years.

resultsBowel QoL data at 3years revealed no significant difference among regimens (p=0.469). Bowel QoL for all regimens declined transiently, largely recovering by three years, with only the 22 fraction decrement reaching significance. Bladder outcomes at 3 years were comparable (p=0.343) although, for all patients combined, a significant decline was observed from the baseline (p=0.008). Spitzer quality of life data revealed similarly excellent, 3-year means (p=0.188). International erectile function data also revealed no significant differences at 3 years although all measures except intercourse satisfaction worsened post-treatment.

conclusionsThree-year QoL changes for bowel, bladder and SQLI were modest and similar for 3 HPFX regimens spanning 2.94-4.3 Gy per fraction. These favorable patient-scored outcomes demonstrate the safety and tolerability of such regimens and may be leveraged to support further implementation of mild to moderately hypofractionated radiotherapy in the setting of low and intermediate-risk prostate cancer.

Indexed as

Quality of LifeAgedAged, 80 and overHumansIntestinesMaleMiddle AgedPenile ErectionProstatic NeoplasmsRadiation Dose HypofractionationRadiotherapy DosageSurveys and QuestionnairesUrinary BladderHypofractionationProstateQuality of lifeSBRT

Identifiers

PMID26755165
PMCPMC4764419

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.